1090 related articles for article (PubMed ID: 30030656)
21. Clinical utility of circulating tumour cell detection in non-small-cell lung cancer.
Fusi A; Metcalf R; Krebs M; Dive C; Blackhall F
Curr Treat Options Oncol; 2013 Dec; 14(4):610-22. PubMed ID: 23996475
[TBL] [Abstract][Full Text] [Related]
22. The role of circulating free DNA in the management of NSCLC.
Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
[TBL] [Abstract][Full Text] [Related]
23. Liquid Biopsy and Lung Cancer.
Pisapia P; Malapelle U; Troncone G
Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
[TBL] [Abstract][Full Text] [Related]
24. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
Chen X; Wang L; Lou J
Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
[TBL] [Abstract][Full Text] [Related]
25. Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer.
Andrikou K; Rossi T; Verlicchi A; Priano I; Cravero P; Burgio MA; Crinò L; Bandini S; Ulivi P; Delmonte A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003273
[TBL] [Abstract][Full Text] [Related]
26. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman P; Heeke S; Alix-Panabières C; Pantel K
Ann Oncol; 2019 Sep; 30(9):1448-1459. PubMed ID: 31228184
[TBL] [Abstract][Full Text] [Related]
27. Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer.
Chen X; Wang X; He H; Liu Z; Hu JF; Li W
PLoS One; 2015; 10(5):e0126276. PubMed ID: 25996878
[TBL] [Abstract][Full Text] [Related]
28. Letter to the Editor: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
Nicolazzo C; Raimondi C; Loreni F; Gazzaniga P; Gradilone A
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629196
[TBL] [Abstract][Full Text] [Related]
29. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
30. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
[TBL] [Abstract][Full Text] [Related]
31. Tumor-educated platelet as liquid biopsy in lung cancer patients.
Liu L; Lin F; Ma X; Chen Z; Yu J
Crit Rev Oncol Hematol; 2020 Feb; 146():102863. PubMed ID: 31935617
[TBL] [Abstract][Full Text] [Related]
32. Tumor-educated platelets.
In 't Veld SGJG; Wurdinger T
Blood; 2019 May; 133(22):2359-2364. PubMed ID: 30833413
[TBL] [Abstract][Full Text] [Related]
33. Liquid biopsy for lung cancer screening: Usefulness of circulating tumor cells and other circulating blood biomarkers.
Hofman P
Cancer Cytopathol; 2021 May; 129(5):341-346. PubMed ID: 33007153
[TBL] [Abstract][Full Text] [Related]
34. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.
Guibert N; Pradines A; Farella M; Casanova A; Gouin S; Keller L; Favre G; Mazieres J
Lung Cancer; 2016 Oct; 100():1-4. PubMed ID: 27597273
[TBL] [Abstract][Full Text] [Related]
35. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
[TBL] [Abstract][Full Text] [Related]
36. Advanced liquid biopsy technologies for circulating biomarker detection.
Soda N; Rehm BHA; Sonar P; Nguyen NT; Shiddiky MJA
J Mater Chem B; 2019 Nov; 7(43):6670-6704. PubMed ID: 31646316
[TBL] [Abstract][Full Text] [Related]
37. Predictive and prognostic value of circulating tumor cell detection in lung cancer: a clinician's perspective.
Tognela A; Spring KJ; Becker T; Caixeiro NJ; Bray VJ; Yip PY; Chua W; Lim SH; de Souza P
Crit Rev Oncol Hematol; 2015 Feb; 93(2):90-102. PubMed ID: 25459665
[TBL] [Abstract][Full Text] [Related]
38. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer.
Nagasaka M; Uddin MH; Al-Hallak MN; Rahman S; Balasubramanian S; Sukari A; Azmi AS
Mol Cancer; 2021 Jun; 20(1):82. PubMed ID: 34074295
[TBL] [Abstract][Full Text] [Related]
39. Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer.
Romero A; Serna-Blasco R; Calvo V; Provencio M
Curr Treat Options Oncol; 2021 Aug; 22(10):86. PubMed ID: 34424428
[TBL] [Abstract][Full Text] [Related]
40. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.
Tissot C; Toffart AC; Villar S; Souquet PJ; Merle P; Moro-Sibilot D; Pérol M; Zavadil J; Brambilla C; Olivier M; Couraud S
Eur Respir J; 2015 Dec; 46(6):1773-80. PubMed ID: 26493785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
